BofA/Merrill Lynch Downgrades Dr. Reddy's Laboratories (RDY) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Morgan Stanley Downgrades Dr. Reddy's Laboratories (RDY) to Equalweight
May 14, 2014 7:32 AM EDTMorgan Stanley downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Dr. Reddy's Laboratories click here. For more ratings news on Dr. Reddy's Laboratories click here.
Shares of Dr. Reddy's Laboratories closed at $43.82 yesterday.
... MoreDr. Reddys Labs (RDY) Reports Q4 EPS of $0.47
May 13, 2014 7:03 AM EDTDr. Reddys Labs (NYSE: RDY) reported Q4 EPS of $0.47, versus $0.56 reported last year. Revenue for the quarter came in at $580 million, versus $557 million reported last year.
For earnings history and earnings-related data on Dr. Reddys Labs (RDY) click here.
... More